Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares OutstandingShares Outstanding
Ratios

Myomo (MYO) EBIAT (2017 - 2025)

Myomo filings provide 9 years of EBIAT readings, the most recent being -$3.7 million for Q3 2025.

  • On a quarterly basis, EBIAT fell 279.02% to -$3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$12.0 million, a 43.37% decrease, with the full-year FY2024 number at -$6.2 million, up 24.1% from a year prior.
  • EBIAT hit -$3.7 million in Q3 2025 for Myomo, up from -$4.6 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$260081.0 in Q4 2024 to a low of -$4.6 million in Q2 2025.
  • Median EBIAT over the past 5 years was -$2.6 million (2023), compared with a mean of -$2.5 million.
  • Biggest five-year swings in EBIAT: skyrocketed 89.43% in 2024 and later tumbled 312.98% in 2025.
  • Myomo's EBIAT stood at -$2.8 million in 2021, then grew by 21.82% to -$2.2 million in 2022, then dropped by 13.5% to -$2.5 million in 2023, then skyrocketed by 89.43% to -$260081.0 in 2024, then tumbled by 1308.37% to -$3.7 million in 2025.
  • The last three reported values for EBIAT were -$3.7 million (Q3 2025), -$4.6 million (Q2 2025), and -$3.5 million (Q1 2025) per Business Quant data.